PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC)
Clinical trials for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough ovarian cancer? early trial launches
Disease control Not yet recruitingThis early-phase study tests a new drug called WSK-IM02 in 36 women whose ovarian cancer has stopped responding to platinum chemotherapy. The main goal is to check the drug's safety and find the right dose, not to cure the disease. Participants will be closely monitored for side …
Matched conditions: PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC)
Phase: PHASE1 • Sponsor: WestVac Biopharma Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 09:48 UTC
-
New hope for women with resistant ovarian cancer: drug combo shows promise
Disease control Not yet recruitingThis study tests a combination of two drugs, sacituzumab tirumotecan and bevacizumab, in 30 women with platinum-resistant recurrent ovarian cancer. The goal is to see if the combo can shrink tumors and delay cancer growth better than current options. Participants must have had 1 …
Matched conditions: PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated May 17, 2026 09:35 UTC